# About Thymosin Alpha-1 Source: An Independent Research Digest

> About Thymosin Alpha-1 Source — an independent editorial project summarizing the peer-reviewed research on Thymosin Alpha-1. Not a clinic, not a vendor, not medical advice.

An independent reading desk for the immune-peptide literature — forward-looking, evidence-graded, and honest about the gaps.

## What this site is

Thymosin Alpha-1 Source is an independent editorial project that publishes plain-English summaries of the peer-reviewed research literature on Thymosin Alpha-1. We read the science forward — surfacing what the trials established and where the field may be heading — while grading the evidence honestly, which means giving the null phase-3 sepsis result the same prominence as the encouraging hepatitis data. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

## What "Source" means here

The word "source" in our name is editorial framing, not a commercial claim. We are a source of *summaries and citations* — a place to read the literature, not a place to obtain the peptide. We do not sell Thymosin Alpha-1, do not link to vendors, and take no position on where anyone might acquire research material. The name describes the position we occupy relative to the published record: a sourcing point for the science, not the substance.

## How we work

Every quantitative statement on this site maps to a numbered citation in our [Thymosin Alpha-1 references](/references), drawn from PubMed, primary journals, and regulatory documents. We describe research findings in the third person and attribute them to their studies; we do not recommend doses, do not give treatment instructions, and do not phrase community anecdotes as proven outcomes. Reported real-world impressions are clearly labeled as anecdote and kept separate from cited findings. When the strongest trial is null, we say so plainly — that honesty is the point of the project.

## What we are careful about

We keep Thymosin Alpha-1 distinct from the molecules it is routinely confused with — thymosin beta-4 (TB-500), thymulin, thymopentin, thymalin, and its own precursor prothymosin alpha — because conflation is the single biggest source of misinformation about this compound. We use only generic, scientific names. We note clearly that the peptide is not FDA-approved in the United States. And we frame it accurately as an immune modulator, never as an anabolic, growth, or performance compound.

---

A forward but evidence-graded reading of the Thymosin Alpha-1 record — the four-decade hepatitis and immune-restoration signal read first, the null phase-3 sepsis trial held in plain view, the molecule kept distinct from thymosin beta-4, and the community reports fenced off as unverified; an open reading desk, not a clinic, and nothing here dosed, sourced, prescribed, or sold.